Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder

Erica Zamberletti; Tiziana Rubino; Daniela Parolaro

doi:10.1016/j.pharmthera.2021.107878

Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder

Pharmacol Ther. 2021 Oct:226:107878. doi: 10.1016/j.pharmthera.2021.107878. Epub 2021 Apr 22.

Authors

Erica Zamberletti¹, Tiziana Rubino², Daniela Parolaro³

Affiliations

¹ Dept. of Biotechnology and Life Sciences (DBSV) and Neuroscience Center, University of Insubria, Busto Arsizio, Italy. Electronic address: erica.zamberletti@uninsubria.it.
² Dept. of Biotechnology and Life Sciences (DBSV) and Neuroscience Center, University of Insubria, Busto Arsizio, Italy.
³ Dept. of Biotechnology and Life Sciences (DBSV) and Neuroscience Center, University of Insubria, Busto Arsizio, Italy; Zardi-Gori Foundation, Milan, Italy. Electronic address: dparolaro@fondazionezardigori.com.

PMID: 33895189
DOI: 10.1016/j.pharmthera.2021.107878

Abstract

Recent years have seen a renewed interest on the possible therapeutic exploitations of specific cannabinoids derived from the Cannabis sativa plant. Thus far, the most studied non-psychotomimetic cannabinoid is cannabidiol (CBD), which has shown promising therapeutic potential for relieving a variety of neurological diseases. However, also its propyl analogue, cannabidivarin (CBDV), has recently gained much attention as a potential therapeutic agent for the management of disabling neurological conditions. This review aims at providing a comprehensive and updated overview of the available animal and human data, which have investigated the possible therapeutic potential of CBDV for the management of epilepsy and autism spectrum disorder.

Keywords: Animal models; Autism spectrum disorder; Cannabidivarin; Epilepsy; Human data.

Publication types

Review

MeSH terms

Animals
Autism Spectrum Disorder* / drug therapy
Cannabinoids* / therapeutic use
Epilepsy* / drug therapy
Humans

Substances

Cannabinoids
cannabidivarin